Hansen, Doris K. https://orcid.org/0000-0002-9813-3578
Dima, Danai
Mian, Hira https://orcid.org/0000-0003-1584-1067
Devos, Jakob
Brazauskas, Ruta
Oloyede, Temitope
Afrough, Aimaz https://orcid.org/0000-0003-2645-8557
Ahmed, Nausheen https://orcid.org/0000-0003-4336-4982
Anderson, Larry https://orcid.org/0000-0002-6531-9595
Banerjee, Rahul https://orcid.org/0000-0003-3781-5441
Berdeja, Jesus G. https://orcid.org/0000-0003-4362-0376
Bidikian, Aram
Dhakal, Binod https://orcid.org/0000-0002-4377-9742
Dias, Ajoy
Efebera, Yvonne
Faisal, Muhammad Salman
Gowda, Lohith
Hashmi, Hamza https://orcid.org/0000-0002-4129-5867
Mirza, Abu-Sayeef https://orcid.org/0000-0002-1875-8966
Mohan, Meera https://orcid.org/0000-0002-6913-6526
Narra, Ravi
Rosko, Ashley E.
Schroeder, Mark https://orcid.org/0000-0003-4924-8990
Nishihori, Taiga https://orcid.org/0000-0002-2621-7924
Landau, Heather https://orcid.org/0000-0002-3152-1189
Usmani, Saad https://orcid.org/0000-0002-5484-8731
Pasquini, Marcelo C.
Akhtar, Othman S.
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
Patel, Krina K. https://orcid.org/0000-0002-8894-027X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U24CA076518)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U24CA076518)
U.S. Department of Health & Human Services | Health Resources and Services Administration (75R60222C00011)
U.S. Department of Health & Human Services | Health Resources and Services Administration (75R60222C00011)
U.S. Department of Health & Human Services | Health Resources and Services Administration (75R60222C00011)
U.S. Department of Health & Human Services | Health Resources and Services Administration (75R60222C00011)
United States Department of Defense | United States Navy | Office of Naval Research (N00014-25-1-2146)
United States Department of Defense | United States Navy | Office of Naval Research (N00014-25-1-2146)
United States Department of Defense | United States Navy | Office of Naval Research (N00014-25-1-2146)
United States Department of Defense | United States Navy | Office of Naval Research (N00014-25-1-2146)
Article History
Received: 4 December 2025
Revised: 13 February 2026
Accepted: 25 March 2026
First Online: 14 April 2026
Competing interests
: DKH receives research funding from Bristol Myers Squibb, Janssen, Kite Pharma, Karyopharm, and Adaptive Biotech, and reports consulting or advisory roles with Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm. DD reports consulting for Karyopharm and Caribou Biosciences. HM receives honoraria from Bristol Myers Squibb, Pfizer, Janssen, Amgen, Takeda, GSK, FORUS, and Sanofi, and research funding from Pfizer and Janssen. AA receives research funding from AbbVie, Regeneron Pharmaceuticals, K36-Therapeutics, Janssen, and Adaptive Biotech, and honoraria from Karyopharm, Bristol Myers Squibb, Janssen, Sanofi, and Pfizer. NA receives research funding from Kite/Gilead and Pfizer and has consulting or advisory roles with Bristol Myers Squibb, Kite/Gilead, Invivyd Bio, Legend Bio, Johnson & Johnson, Autolus, and ADC Therapeutics; founder of Cortex (non-profit) and board member of USMIRC. LA receives consulting fees and honoraria from Pfizer, Bristol Myers Squibb, BeiGene, Sanofi, Amgen, Karyopharm, Celgene, Prothena, Cellectar, Johnson & Johnson, GSK, and AbbVie, and research funding from Bristol Myers Squibb, BeiGene, Johnson & Johnson, GSK, and AbbVie. RB reports consulting for AbbVie, Adaptive Biotech, Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Poseida Therapeutics, Sanofi, and SparkCures, and receives research funding from AbbVie, Bristol Myers Squibb, Janssen, Novartis, Pack Health, Prothena, and Sanofi. MM is supported by the Advancing a Healthier Wisconsin CTSI KL2 award, receives institutional research funding from Sanofi, Bristol Myers Squibb, and Celgene, and reports consulting for Sanofi, Bristol Myers Squibb/Celgene, Pfizer, Janssen Scientific Affairs, Legend Biotech, and Adaptive Biotech. SS reports consulting for Janssen, Bristol Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, AbbVie, Regeneron, BiolineRx, and Genentech/Roche, and receives research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis, and Bristol Myers Squibb. KKP reports consulting for Bristol Myers Squibb, Janssen, Pfizer, Arcellx, and Karyopharm Therapeutics, research funding from Bristol Myers Squibb, Poseida Therapeutics, Takeda, Janssen, Cellectis, Nektar, AbbVie/Genentech, Precision Biosciences, and Allogene Therapeutics, and travel support from Bristol Myers Squibb. ASM reports consulting for Bristol Myers Squibb. MCP receives honoraria from Gilead and research funding from Kite/Gilead, Janssen, Bristol Myers Squibb, and Novartis. HH reports consulting for Bristol Myers Squibb, Sanofi, and Janssen. YE receives honoraria from Pfizer, GSK, Kite, Janssen, Sanofi, Bristol Myers Squibb, Orca, and Oncopeptides, and research funding via Pharmacyclics (Alliance) and GSK (Alliance). BD receives honoraria from Natera, GlaxoSmithKline, Menarini, Kite, and Janssen, consulting for Genentech, Caribou, Johnson & Johnson, Karyopharm, Bristol Myers Squibb, Janssen, Arcellx, and Pfizer, and research funding from Caribou, Ichnos, Kite, Carsgen, Bristol Myers Squibb, Janssen, Arcellx, and Pfizer. SU reports consulting or advisory roles with GSK, Takeda, SecuraBio, Amgen, Seagen, Johnson & Johnson/Janssen, Genentech, Sanofi, Gilead, Oncopeptides, Bristol Myers Squibb/Celgene, SkylineDX, AbbVie, EdoPharma, Gracell Therapeutics, TeneoBio, and AstraZeneca, and receives research funding from Janssen, Takeda, SecuraBio, Amgen, Seagen, Johnson & Johnson/Janssen, Sanofi, Gilead, Oncopeptides, Bristol Myers Squibb/Celgene, SkylineDX, AbbVie, EdoPharma, Gracell Therapeutics, and TeneoBio. OSA reports advisory board participation for Sanofi and Janssen, and consulting for Immix Biopharma. All remaining authors report no financial relationships relevant to this work.
: All Center for International Blood and Marrow Transplant Research studies are reviewed and approved by the National Marrow Donor Program Institutional Review Board, and all patients (or their legal guardians) provided informed consent for data collection and research.